JP2022517730A5 - - Google Patents
Info
- Publication number
- JP2022517730A5 JP2022517730A5 JP2021536757A JP2021536757A JP2022517730A5 JP 2022517730 A5 JP2022517730 A5 JP 2022517730A5 JP 2021536757 A JP2021536757 A JP 2021536757A JP 2021536757 A JP2021536757 A JP 2021536757A JP 2022517730 A5 JP2022517730 A5 JP 2022517730A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- phenyl
- alkyl
- pharmaceutically acceptable
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023005014A JP2023052437A (ja) | 2018-12-27 | 2023-01-17 | がんの処置のためのｔｇｆ－ベータｒ１（ａｌｋ５）阻害剤としての（ピリジン－２－イル）アミン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785616P | 2018-12-27 | 2018-12-27 | |
| US62/785,616 | 2018-12-27 | ||
| PCT/US2019/066993 WO2020139636A1 (en) | 2018-12-27 | 2019-12-17 | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023005014A Division JP2023052437A (ja) | 2018-12-27 | 2023-01-17 | がんの処置のためのｔｇｆ－ベータｒ１（ａｌｋ５）阻害剤としての（ピリジン－２－イル）アミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517730A JP2022517730A (ja) | 2022-03-10 |
| JP2022517730A5 true JP2022517730A5 (https=) | 2022-12-16 |
| JP7515049B2 JP7515049B2 (ja) | 2024-07-12 |
Family
ID=69185691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536757A Active JP7515049B2 (ja) | 2018-12-27 | 2019-12-17 | がんの処置のためのｔｇｆ－ベータｒ１（ａｌｋ５）阻害剤としての（ピリジン－２－イル）アミン誘導体 |
| JP2023005014A Pending JP2023052437A (ja) | 2018-12-27 | 2023-01-17 | がんの処置のためのｔｇｆ－ベータｒ１（ａｌｋ５）阻害剤としての（ピリジン－２－イル）アミン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023005014A Pending JP2023052437A (ja) | 2018-12-27 | 2023-01-17 | がんの処置のためのｔｇｆ－ベータｒ１（ａｌｋ５）阻害剤としての（ピリジン－２－イル）アミン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12102626B2 (https=) |
| EP (1) | EP3902796B1 (https=) |
| JP (2) | JP7515049B2 (https=) |
| KR (1) | KR102832376B1 (https=) |
| CN (1) | CN113348167B (https=) |
| AR (1) | AR117539A1 (https=) |
| AU (1) | AU2019417418B2 (https=) |
| BR (1) | BR112021007006A2 (https=) |
| CA (1) | CA3117838A1 (https=) |
| EA (1) | EA202191619A1 (https=) |
| ES (1) | ES2972516T3 (https=) |
| IL (1) | IL284266B2 (https=) |
| MX (1) | MX2021007738A (https=) |
| SG (1) | SG11202103457PA (https=) |
| TW (1) | TWI884934B (https=) |
| WO (1) | WO2020139636A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021259419A1 (en) | 2020-04-21 | 2022-11-10 | Lexicon Pharmaceuticals, Inc. | AAK1 inhibitors for use in treating viral infections |
| AU2021258128A1 (en) | 2020-04-21 | 2022-11-03 | Lexicon Pharmaceuticals, Inc. | 4-(3-(pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-5-yl)piperazine for use in the the treatment of COV-229E or COV-OC43 coronaviruses infections |
| CN113214111A (zh) * | 2021-04-30 | 2021-08-06 | 上海立科化学科技有限公司 | 3-（2-氰基苯基）丙酸及4-氰基-1-茚满酮的制备方法 |
| US12263576B2 (en) | 2021-08-19 | 2025-04-01 | Hyundai Mobis Co., Ltd. | Robot system for automated assembly of modular component |
| EP4464694A4 (en) * | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN121554469B (zh) * | 2026-01-23 | 2026-04-17 | 四川大学华西医院 | 一种alk5 protac化合物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287857B6 (sk) | 2001-05-24 | 2012-01-04 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| JP5934782B2 (ja) * | 2011-05-04 | 2016-06-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | アミノ−ピリジン含有脾臓チロシンキナーゼ（Ｓｙｋ）阻害薬 |
| WO2014048065A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| EP2934525B1 (en) * | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| WO2014155300A2 (en) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| PL3089971T3 (pl) | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Związki i sposoby ich zastosowania |
| CN106536507B (zh) | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
| TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| WO2016201370A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP2018520201A (ja) | 2015-07-23 | 2018-07-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｇｆベーター受容体アンタゴニスト |
| WO2020103817A1 (zh) | 2018-11-20 | 2020-05-28 | 南京圣和药业股份有限公司 | TGF-βR1抑制剂及其应用 |
| JP7499284B2 (ja) | 2019-06-25 | 2024-06-13 | インベンティスバイオ カンパニー リミテッド | 複素環化合物、その製造方法及びその使用方法 |
| CN112707902B (zh) | 2020-03-23 | 2022-04-15 | 杭州阿诺生物医药科技有限公司 | TGF-β受体抑制剂 |
-
2019
- 2019-12-17 AU AU2019417418A patent/AU2019417418B2/en active Active
- 2019-12-17 MX MX2021007738A patent/MX2021007738A/es unknown
- 2019-12-17 BR BR112021007006-0A patent/BR112021007006A2/pt unknown
- 2019-12-17 EA EA202191619A patent/EA202191619A1/ru unknown
- 2019-12-17 KR KR1020217021785A patent/KR102832376B1/ko active Active
- 2019-12-17 IL IL284266A patent/IL284266B2/en unknown
- 2019-12-17 US US17/299,696 patent/US12102626B2/en active Active
- 2019-12-17 SG SG11202103457PA patent/SG11202103457PA/en unknown
- 2019-12-17 CN CN201980086920.0A patent/CN113348167B/zh active Active
- 2019-12-17 WO PCT/US2019/066993 patent/WO2020139636A1/en not_active Ceased
- 2019-12-17 EP EP19839715.0A patent/EP3902796B1/en active Active
- 2019-12-17 JP JP2021536757A patent/JP7515049B2/ja active Active
- 2019-12-17 ES ES19839715T patent/ES2972516T3/es active Active
- 2019-12-17 CA CA3117838A patent/CA3117838A1/en active Pending
- 2019-12-25 TW TW108147526A patent/TWI884934B/zh active
- 2019-12-27 AR ARP190103894A patent/AR117539A1/es unknown
-
2023
- 2023-01-17 JP JP2023005014A patent/JP2023052437A/ja active Pending
-
2024
- 2024-08-05 US US18/795,000 patent/US20240398776A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517730A5 (https=) | ||
| JP2013525458A5 (https=) | ||
| JP2016517417A5 (https=) | ||
| JP2021523221A5 (https=) | ||
| JP2022545359A5 (https=) | ||
| JP2006515858A5 (https=) | ||
| JP2012507566A5 (https=) | ||
| JP2005530722A5 (https=) | ||
| JP2013505969A5 (https=) | ||
| JP2004506718A5 (https=) | ||
| JP2004504301A5 (https=) | ||
| JP2016520131A5 (https=) | ||
| JP2016532673A5 (https=) | ||
| JP2017528467A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| JP2010539110A5 (https=) | ||
| JP2017533968A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| HRP20161177T1 (hr) | Modulator glukagonskog receptora | |
| JP2016508130A5 (https=) | ||
| JP2014528466A5 (https=) | ||
| JP2014506599A5 (https=) | ||
| RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| SI3140296T1 (en) | PIROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES AS SUITABLE DISEASE |